About Aprecia Pharmaceuticals
Aprecia Pharmaceuticals is a Healthcare company based in Langhorne (United States) founded in 2003. It develops manufactures orodispersible formulations of highly prescribed high-dose medications using proprietary drug delivery systems. It operates in the Healthcare and Technology sectors. Aprecia Pharmaceuticals has raised $176.49 million across 11 funding rounds from investors including Hercules Capital and Deerfield. The company has 87 employees. Its chief executive is Owen Murray. The company has since been acquired. Aprecia Pharmaceuticals offers products and services including Development Services and Manufacturing Services. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Diversified. Its competitors include Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Korro Bio and 5 more; 8 of its 10 listed competitors have raised funding.
Company details
Aprecia Pharmaceuticals develops and manufactures orodispersible tablets with a focus on high-dose medications using ZipDose Technology. ZipDose Technology utilizes its proprietary three-dimensional printing (3DP) platform. This process stitches together multiple layers of powdered medication using an aqueous fluid to produce a porous, water-soluble matrix that rapidly disintegrates with a sip of liquid. FDA has recently approved SPRITAM levetiracetam for oral use as a prescription adjunctive therapy in the treatment of partial onset seizures, myoclonic seizures and primary generalized tonic-clonic seizures in adults and children with epilepsy. SPRITAM utilizes its proprietary ZipDose Technology platform to produce a porous formulation that rapidly disintegrates with a sip of liquid. It plans to introduce multiple new products utilizing ZipDose Technology, focusing first on the central nervous system therapeutic area.
- Headquarters Langhorne, United States
- Employees 87
- Stage Acquired
- SectorsHealthcareTechnology
- Website category Health · Biotechnology and Pharmaceuticals
- Website aprecia.com
- Social LinkedIn X
- Legal Name Aprecia Pharmaceuticals
- Total Equity Funding$176.49M (USD)
in 11 rounds
- Latest Funding Round$20M (USD), Debt – Venture
Jul 2016
- InvestorsHercules Capital
& 2 more
- Employee Count87
Products & Services of Aprecia Pharmaceuticals
Aprecia Pharmaceuticals offers a comprehensive portfolio of products and services, including Development Services and Manufacturing Services.
Collaborates on formulations and 3D printing to accelerate pharmaceutical development.
Provides flexible cGMP-compliant manufacturing for clinical and commercial needs.
Funding Insights of Aprecia Pharmaceuticals
Aprecia Pharmaceuticals has successfully raised a total of $176.49M across 11 strategic funding rounds. The most recent funding activity was a Debt – Venture round of $20 million completed in July 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $176.49M
- Total Rounds 11
- Last Round Debt – Venture — $20M
- First Round $550,000
(Mar 2006)
- Investors Count 2
Latest 10 of 11 funding rounds of Aprecia Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2016 | $20M | Debt – Venture | – | – | |
| Jan 2016 | $79M | Series D | – | Deerfield | – |
| Aug 2015 | $38.75M | Series D | – | – | – |
| Dec 2013 | $14.89M | Series C | – | – | – |
| Nov 2012 | $4M | Series C | – | – | – |
| Nov 2011 | $25.73M | Series C | – | – | – |
| Dec 2010 | $3.94M | Series B | – | – | – |
| Jan 2010 | $5.5M | Series B | – | – | – |
| May 2009 | $500,000 | Series A | – | – | – |
| Jan 2008 | $3.63M | Series A | – | – | – |
2 investors in total: 2 institutional.
Investors in Aprecia Pharmaceuticals
Aprecia Pharmaceuticals has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Hercules Capital and Deerfield.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture debt financing is provided to companies in multiple sectors. | 2003 | htgc.com | Palo Alto, United States | |
Healthcare ecosystem is supported through investment and innovation by Deerfield. | – | deerfield.com | New York, United States |
Investor details for Aprecia Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Aprecia Pharmaceuticals
30 people are tracked at Aprecia Pharmaceuticals (15 in leadership, 2 in board & advisors, 13 in team); the tracked headcount is 87.
| Name | Role | Group |
|---|---|---|
Owen Murray | CEO | Leadership |
Christopher E. Gilmore | CEO | Leadership |
Garry Hedgepeth | VP, Quality | Leadership |
Kyle Smith | President & Chief Operating Officer | Leadership |
Mike Gosselin | VP, Pharmaceutical Development | Leadership |
Andrew Karazim | Chief Commercial Officer (cco) | Leadership |
Patrick Staudt | Vice President Operations | Leadership |
Christopher Lockwood | Senior Director, Product Development | Leadership |
Jacob Mayer | Director Of Engineering Innovation | Leadership |
Don Monkhouse | President | Leadership |
Rob Williford | COO | Leadership |
Ted Kremer | Senior Director Of Operations | Leadership |
Mike Mayfield | Director, Quality Control / Analytical Development | Leadership |
Amanda Kleiman | Vice President , Marketing And Communications | Leadership |
Tyler Iverson | Director Of Operations | Leadership |
E. Thomas Arington | Chairman | Board & advisors |
Mahendra Patel | Scientific Advisor | Board & advisors |
Donald Wetherhold | Senior Executive Advisor & SVP | Team |
Joe Deluca | Facility Manager | Team |
Randall Butcher | Lead Operator Manufacturing | Team |
10 more people are available in the full profile.
Complete people profiles for Aprecia Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Aprecia Pharmaceuticals
3 dated milestones of Aprecia Pharmaceuticals across 13 years, from founding to its latest funding, stage changes and deals.
- Founded Aprecia Pharmaceuticals is founded.
- Funding First funding round of $550K.
- Funding Latest funding round, Debt – Venture, of $20.0M.
Competitors of Aprecia Pharmaceuticals
Aprecia Pharmaceuticals has 10 listed competitors in our database, 8 of them funded. They include Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Korro Bio, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| univercells.com | 2013 | Charleroi, Belgium | $150.64M | 87 | Biomanufacturing technologies are supplied for biopharma antibody and vaccine production. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform | |
| korrobio.com | 2018 | Cambridge, United States | $4M | 77 | RNA-editing technologies are provided for precision medicine applications. | |
| straumann.com | 1954 | Basel, Switzerland | – | – | Dental implants and regenerative dentistry products are developed. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. | |
| judges.uk.com | 2002 | London, United Kingdom | – | 622 | Acquisition and development of scientific instrument businesses is conducted. | |
| savarapharma.com | 2008 | Austin, United States | $67.82M | 37 | Therapeutics for rare respiratory diseases are developed by Savara Pharma. | |
| synthego.com | 2012 | Redwood, United States | $459.75M | – | CRISPR-engineered cell and gene therapies are developed for research applications. |
Detailed competitors of Aprecia Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Aprecia Pharmaceuticals
The website of Aprecia Pharmaceuticals (aprecia.com) receives about 2.6K visits a month and ranks #5,861,353 among all websites worldwide, #6,284 in Biotechnology and Pharmaceuticals.
- Monthly visits2.6K
▼ 6.2% vs previous month
- Unique visitors1.1K
per month
- Global rank#5,861,353
among all websites
- Category rank#6,284
Health · Biotechnology and Pharmaceuticals
- Bounce rate39%
- Pages per visit1.8
- Average visit30 sec
- DevicesDesktop 30% · Mobile 70%
Websites whose visitors overlap most with Aprecia Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| irisys.com | 100% | – | – | View details | |
| intecpharma.com | 99% | – | – | View details | |
| dptlabs.com | 99% | 1.5K | #8,022,749 | View details | |
| bendresearch.com | 99% | – | – | View details | |
novogen.com | novogen.com | 99% | – | – | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 7 similar websites and full traffic analytics for Aprecia Pharmaceuticals
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 7 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
10 companies that operate in the same segment as Aprecia Pharmaceuticals (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | 1,111 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Aprecia Pharmaceuticals
Complete news archive for Aprecia Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aprecia Pharmaceuticals
Aprecia Pharmaceuticals was founded in 2003 and raised its 1st funding round 3 years after it was founded.
Aprecia Pharmaceuticals is headquartered in Langhorne, United States. It is registered at Langhorne, Pennsylvania, United States.
Owen Murray is the current CEO of Aprecia Pharmaceuticals.
Aprecia Pharmaceuticals is a funded company, having raised a total of $176.49M across 11 funding rounds to date. The company's 1st funding round was a Series A of $3.63M, raised on Mar 2006.
Aprecia Pharmaceuticals has 87 employees.
Aprecia Pharmaceuticals develops and manufactures orodispersible tablets with a focus on high-dose medications using ZipDose Technology. ZipDose Technology utilizes its proprietary three-dimensional printing (3DP) platform. This process stitches together multiple layers of powdered medication using an aqueous fluid to produce a porous, water-soluble matrix that rapidly disintegrates with a sip of liquid. FDA has recently approved SPRITAM levetiracetam for oral use as a prescription adjunctive therapy in the treatment of partial onset seizures, myoclonic seizures and primary generalized tonic-clonic seizures in adults and children with epilepsy. SPRITAM utilizes its proprietary ZipDose Technology platform to produce a porous formulation that rapidly disintegrates with a sip of liquid. It plans to introduce multiple new products utilizing ZipDose Technology, focusing first on the central nervous system therapeutic area.
Aprecia Pharmaceuticals's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Aprecia Pharmaceuticals offers Development Services and Manufacturing Services.
Aprecia Pharmaceuticals has 2 investors. Key investors include Hercules Capital, and Deerfield.
Aprecia Pharmaceuticals operates through Aprecia Pharmaceuticals.